Latest news with #Relonchem
Business Standard
5 days ago
- Business
- Business Standard
Marksans Pharma gets regulatory nod for marketing type-2 diabetes medication in UK
Marksans Pharma said that its UK-based wholly owned subsidiary Relonchem has received marketing authorization for Metformin Hydrochloride oral solution product from UK Medicines & Healthcare Products Regulatory Agency. Metformin Hydrochloride is a widely prescribed medication used for the management of type-2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. This regulatory approval would enable Marksans Pharma to market and distribute the said oral solution in the UK. Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. The scrip rose 0.38% to currently trade at Rs 261.35 on the BSE.
&w=3840&q=100)
Business Standard
15-05-2025
- Business
- Business Standard
Here's why Marksans Pharma share price increased over 2% in trade on May 15
Marksans Pharma share price: Pharmaceutical company Marksans Pharma shares rose up to 2.18 per cent to hit an intraday high of ₹243.40 per share on Thursday, May 15, 2025. However, at 11:20 PM, Marksans Pharma shares pared gains and were trading merely 0.08 per cent higher at ₹238 per share. In comparison, BSE Sensex was trading 0.10 per cent lower at 81,247.08 level. Why led to the up move in Marksans Pharma share price? The northward move in Marksans Pharma came after the company's wholly-owned subsidiary, Relonchem, received marketing authorisation for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency (UK MHRA). In an exchange filing, Marksans Pharma said, 'Marksans Pharma hereby announces that its wholly owned subsidiary Relonchem Limited has received marketing authorisation for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.' Gabapentin is commonly used to treat epilepsy and nerve pain. In epilepsy, it's believed to work by calming abnormal electrical activity in the brain that leads to seizures. It's also effective for managing nerve pain, which may result from conditions such as diabetes, shingles, or physical injuries. Marksans Pharma results Marksans Pharma will release its March quarter of financial year 2025 (Q4FY25) results on May 19. The board will also consider recommending a dividend on the equity shares for FY25. In Q3FY25, Marksans Pharma's operating revenue stood at ₹681.8 crore, up 16.3 per cent year-on-year (Y-o-Y), driven growth across key markets, led by US region The gross profit stood at ₹383.5 crore, up 22.4 per cent Y-o-Y, with a gross margin expansion of 279 basis points (bps) Y-o-Y to 56.2 per cent. The growth was attributed to softening of raw material prices and a better product mix, the company said in a statement. About Marksans Pharma Marksans Pharma, based in Mumbai, specialises in the research, manufacturing, and marketing of generic pharmaceutical formulations in global markets. The company operates manufacturing facilities in India, the USA, and the UK, all of which are approved by regulatory agencies, including the USFDA, UKMHRA, and Australian TGA. Marksans Pharma offers a diverse product portfolio across key therapeutic areas, such as cardiovascular (CVS), central nervous system (CNS), anti-diabetic, pain management, gastroenterology, and anti-allergies. These products are marketed worldwide.
